NO20014674L - Fremgangsmåte for behandling av neurologiske og neuropsykiatriske forstyrrelser - Google Patents

Fremgangsmåte for behandling av neurologiske og neuropsykiatriske forstyrrelser

Info

Publication number
NO20014674L
NO20014674L NO20014674A NO20014674A NO20014674L NO 20014674 L NO20014674 L NO 20014674L NO 20014674 A NO20014674 A NO 20014674A NO 20014674 A NO20014674 A NO 20014674A NO 20014674 L NO20014674 L NO 20014674L
Authority
NO
Norway
Prior art keywords
neurological
procedures
treatment
neuropsychiatric disorders
neuropsychiatric
Prior art date
Application number
NO20014674A
Other languages
English (en)
Norwegian (no)
Other versions
NO20014674D0 (no
Inventor
Gregory Lynn Willis
Original Assignee
Clarencew Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/285,859 external-priority patent/US6310085B1/en
Application filed by Clarencew Pty Ltd filed Critical Clarencew Pty Ltd
Publication of NO20014674D0 publication Critical patent/NO20014674D0/no
Publication of NO20014674L publication Critical patent/NO20014674L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0618—Psychological treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Radiology & Medical Imaging (AREA)
  • Social Psychology (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
NO20014674A 1996-10-04 2001-09-26 Fremgangsmåte for behandling av neurologiske og neuropsykiatriske forstyrrelser NO20014674L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPO2745A AUPO274596A0 (en) 1996-10-04 1996-10-04 Method for the treatment of neurological or neuropsychiatric disorders
US09/285,859 US6310085B1 (en) 1997-10-03 1999-04-02 Method for the treatment of neurological or neuropsychiatric disorders
PCT/AU2000/000275 WO2000059504A1 (en) 1996-10-04 2000-03-31 Method for the treatment of neurological or neuropsychiatric disorders

Publications (2)

Publication Number Publication Date
NO20014674D0 NO20014674D0 (no) 2001-09-26
NO20014674L true NO20014674L (no) 2001-09-26

Family

ID=37945448

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014674A NO20014674L (no) 1996-10-04 2001-09-26 Fremgangsmåte for behandling av neurologiske og neuropsykiatriske forstyrrelser

Country Status (21)

Country Link
US (1) US20020068692A1 (pt)
EP (2) EP0964679A4 (pt)
JP (2) JP2001503394A (pt)
CN (1) CN1345238A (pt)
AU (3) AUPO274596A0 (pt)
BG (1) BG106065A (pt)
BR (1) BR0009524A (pt)
CA (2) CA2267381A1 (pt)
CZ (1) CZ20013487A3 (pt)
EE (1) EE200100511A (pt)
HU (1) HUP0200287A3 (pt)
IL (1) IL145696A0 (pt)
MA (1) MA25404A1 (pt)
MX (1) MXPA01009963A (pt)
NO (1) NO20014674L (pt)
NZ (1) NZ515023A (pt)
PL (1) PL350961A1 (pt)
SK (1) SK13862001A3 (pt)
TR (1) TR200102864T2 (pt)
WO (2) WO1998015267A1 (pt)
ZA (1) ZA200108592B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO274596A0 (en) * 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
ATE457169T1 (de) 1998-10-15 2010-02-15 Imp Innovations Ltd Verbindungen für die behandlung von gewichtsverlust
SE9803760D0 (sv) * 1998-11-04 1998-11-04 Jan Hedner Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
IL130171A (en) * 1999-05-27 2004-06-01 Neurim Pharma 1991 Melatonin for use in preventing and treating tardive dyskinesia, pharmaceutical preparations containing it and its use in the manufacture of medicines
IL138825A (en) * 2000-10-03 2006-06-11 Neurim Pharma 1991 Pharmaceutical preparations containing tryptamine derivatives and similar compounds, and such new compounds
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
US7303869B2 (en) 2001-07-17 2007-12-04 Northwestern University Solid-phase reactions
US7485443B2 (en) 2001-07-17 2009-02-03 Northwestern University Solid-phase reactions
JP2005219511A (ja) * 2002-02-05 2005-08-18 Azumaya:Kk ハイジャク防止システムおよぴ防止方法
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US7622495B2 (en) 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
GB0701970D0 (en) 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
JP5582535B2 (ja) * 2007-06-29 2014-09-03 クラレンス ピーティーワイ エルティーディー 点眼投与による神経疾患または精神神経疾患の治療または予防
US9662347B2 (en) 2010-05-11 2017-05-30 Gachon University Of Industry-Academic Cooperation Foundation Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system
US9918980B2 (en) * 2011-04-29 2018-03-20 Rutgers, The State University Of New Jersey Method of treating dyskinesia
US10736889B2 (en) * 2011-04-29 2020-08-11 Rutgers, The State University Of New Jersey Method of treating dyskinesia
EP2701707B1 (en) * 2011-04-29 2020-09-02 Rutgers, the State University of New Jersey Method of treating dyskinesia
CA2837823C (en) 2011-05-31 2023-05-16 Clarencew Pty. Ltd Methods for preventing and treating motor-related neurological conditions
GB201416017D0 (en) 2014-09-10 2014-10-22 New Royal Holloway & Bedford An Anticonvulsant Compound
CN116354924A (zh) * 2021-12-27 2023-06-30 江苏恩华药业股份有限公司 一种2-咪唑酮衍生物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468391A (en) * 1982-06-25 1984-08-28 Ayerst, Mckenna & Harrison, Inc. Combination of β-adrenoceptor antagonists and anxiolytic agents
IL79264A0 (en) * 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
US5093352A (en) * 1988-11-14 1992-03-03 Whitby Research, Inc. Antidepressant agents
US5283343A (en) * 1987-08-17 1994-02-01 Whitby Research, Inc. 2-aryl substituted N-acetyltryptamines and process of preparing such
WO1991004072A1 (en) * 1989-09-15 1991-04-04 Donetsky Gosudarstvenny Meditsinsky Institut Imeni M.Gorkogo Device for correcting the emotional state of a person
US5151446A (en) * 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5046494A (en) * 1990-08-27 1991-09-10 John Searfoss Phototherapy method
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US5246944A (en) * 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
FR2680507B1 (fr) * 1991-08-23 1993-10-08 Adir Cie Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2689124A1 (fr) * 1992-03-27 1993-10-01 Adir Nouvelles naphtylalkylamines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
GB2282807A (en) * 1993-10-15 1995-04-19 Merck & Co Inc Tryptophan esters and amides as tachykinin receptor antagonists
GB9407919D0 (en) * 1994-04-21 1994-06-15 Glaxo Group Ltd Chemical compounds
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
AUPO274596A0 (en) * 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
FR2778662B1 (fr) * 1998-05-12 2000-06-16 Adir Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
CA2267381A1 (en) 1998-04-16
HUP0200287A2 (en) 2002-06-29
CA2366850A1 (en) 2000-10-12
AU4372597A (en) 1998-05-05
WO2000059504A1 (en) 2000-10-12
EP0964679A4 (en) 2002-09-11
HUP0200287A3 (en) 2002-12-28
AU3410200A (en) 2000-10-23
MA25404A1 (fr) 2002-04-01
AU782492B2 (en) 2005-08-04
NO20014674D0 (no) 2001-09-26
CN1345238A (zh) 2002-04-17
EP0964679A1 (en) 1999-12-22
CZ20013487A3 (cs) 2003-04-16
US20020068692A1 (en) 2002-06-06
EP1189613A1 (en) 2002-03-27
EP1189613A4 (en) 2004-02-11
JP2002541105A (ja) 2002-12-03
AU736005B2 (en) 2001-07-26
JP2001503394A (ja) 2001-03-13
PL350961A1 (en) 2003-02-24
EE200100511A (et) 2002-12-16
TR200102864T2 (tr) 2002-03-21
WO1998015267A1 (en) 1998-04-16
SK13862001A3 (sk) 2003-04-01
AUPO274596A0 (en) 1996-10-31
IL145696A0 (en) 2002-06-30
MXPA01009963A (es) 2003-07-14
NZ515023A (en) 2004-01-30
ZA200108592B (en) 2002-10-18
BR0009524A (pt) 2002-02-19
BG106065A (en) 2002-04-30

Similar Documents

Publication Publication Date Title
NO996483D0 (no) Imidazopyrimidiner og imidazopyridiner for behandling av neurologiske forstyrrelser
HUP0100815A3 (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
NO20014674D0 (no) Fremgangsmåte for behandling av neurologiske og neuropsykiatriske forstyrrelser
HUP9904361A3 (en) Use of isobutylgaba and its derivatives for the treatment of pain
NO991381L (no) Kombinasjonsterapi for behandling av psykoser
NO20004098D0 (no) FremgangsmÕter og preparater for behandling av makrofag- formidlede lidelser
IL116998A0 (en) Novel indoline compounds processes for their preparation and their use for the treatment of CNS disorders
PT936908E (pt) Derivados anticonvulsivos uteis no tratamento de esclerose lateral amiotrofica (ela)
IL128379A0 (en) Treatment of the common cold or allergic rhinitis
EP0777474A4 (en) METHOD FOR TREATING INFLAMMABLE JOINT DISEASES
BR9707922A (pt) Cafeína e clemastina para tratamento de distúrbios respiratórios
EP0918767A4 (en) PHARMACEUTICAL PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS
NO983512D0 (no) Midler for behandling og forhindring av AIDS
AU1578295A (en) Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders
EP1039883A4 (en) METHOD FOR TREATING APOLIPOPROTEIN E CONDITIONAL DISEASES
PL332313A1 (en) Application of benzopyranoles in treatment of neurological disorders
NO991734D0 (no) Pyrazolinoner for behandling av potensforstyrrelser
NO984432L (no) FremgangsmÕte for behandling av migrenesmerte
EP0981357A4 (en) METHODS AND COMPOSITIONS APPLICABLE TO THE DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS
NO952411D0 (no) Midler for behandling av metaboliske bensykdommer
EP0979234A4 (en) METHODS AND COMPOSITIONS APPLICABLE TO THE DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS
ZA985818B (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders.
HK1044900A1 (zh) 用於治療神經病或神經精神疾病的方法
PT1011678E (pt) Utilização de mecamilamina para o tratamento de perturbações neuropsiquiátricas responsivas à nicotina.
NO984190D0 (no) Fremgangsmåte for behandling av insomnia

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application